{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:50:11Z","timestamp":1775062211900,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004955","name":"\u00d6sterreichische Forschungsf\u00f6rderungsgesellschaft","doi-asserted-by":"publisher","award":["7940628 533"],"award-info":[{"award-number":["7940628 533"]}],"id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005203","name":"OeAD-GmbH","doi-asserted-by":"publisher","award":["SI 29\/2023"],"award-info":[{"award-number":["SI 29\/2023"]}],"id":[{"id":"10.13039\/501100005203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001822","name":"\u00d6sterreichischen Akademie der Wissenschaften","doi-asserted-by":"publisher","award":["DOC fellowship"],"award-info":[{"award-number":["DOC fellowship"]}],"id":[{"id":"10.13039\/501100001822","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Comprehensive Cancer Center Forschungsf\u00f6rderung der Initiative Krebsforschung, MedUni Wien"},{"DOI":"10.13039\/501100001821","name":"Vienna Science and Technology Fund","doi-asserted-by":"publisher","award":["LS18-111"],"award-info":[{"award-number":["LS18-111"]}],"id":[{"id":"10.13039\/501100001821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["116064\u2013ITCC P4"],"award-info":[{"award-number":["116064\u2013ITCC P4"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["J1-1717"],"award-info":[{"award-number":["J1-1717"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Zebrafish xenotransplantation models are increasingly applied for phenotypic drug screening to identify small compounds for precision oncology. Larval zebrafish xenografts offer the opportunity to perform drug screens at high-throughput in a complex in vivo environment. However, the full potential of the larval zebrafish xenograft model has not yet been realized and several steps of the drug screening workflow still await automation to increase throughput. Here, we present a robust workflow for drug screening in zebrafish xenografts using high-content imaging. We established embedding methods for high-content imaging of xenografts in 96-well format over consecutive days. In addition, we provide strategies for automated imaging and analysis of zebrafish xenografts including automated tumor cell detection and tumor size analysis over time. We also compared commonly used injection sites and cell labeling dyes and show specific site requirements for tumor cells from different entities. We demonstrate that our setup allows us to investigate proliferation and response to small compounds in several zebrafish xenografts ranging from pediatric sarcomas and neuroblastoma to glioblastoma and leukemia. This fast and cost-efficient assay enables the quantification of anti-tumor efficacy of small compounds in large cohorts of a vertebrate model system in vivo. Our assay may aid in prioritizing compounds or compound combinations for further preclinical and clinical investigations.<\/jats:p>","DOI":"10.1038\/s41698-023-00386-9","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:02:45Z","timestamp":1684393365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts"],"prefix":"10.1038","volume":"7","author":[{"given":"C.","family":"Sturtzel","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-6738","authenticated-orcid":false,"given":"S.","family":"Grissenberger","sequence":"additional","affiliation":[]},{"given":"P.","family":"Bozatzi","sequence":"additional","affiliation":[]},{"given":"E.","family":"Scheuringer","sequence":"additional","affiliation":[]},{"given":"A.","family":"Wenninger-Weinzierl","sequence":"additional","affiliation":[]},{"given":"Z.","family":"Zajec","sequence":"additional","affiliation":[]},{"given":"J.","family":"Dernov\u0161ek","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2294-8084","authenticated-orcid":false,"given":"S.","family":"Pascoal","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0115-9016","authenticated-orcid":false,"given":"V.","family":"Gehl","sequence":"additional","affiliation":[]},{"given":"A.","family":"Kutsch","sequence":"additional","affiliation":[]},{"given":"A.","family":"Granig","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9956-2382","authenticated-orcid":false,"given":"F.","family":"Rifatbegovic","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0427-7317","authenticated-orcid":false,"given":"M.","family":"Carre","sequence":"additional","affiliation":[]},{"given":"A.","family":"Lang","sequence":"additional","affiliation":[]},{"given":"I.","family":"Valtingojer","sequence":"additional","affiliation":[]},{"given":"J.","family":"Moll","sequence":"additional","affiliation":[]},{"given":"D.","family":"L\u00f6tsch","sequence":"additional","affiliation":[]},{"given":"F.","family":"Erhart","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6014-0273","authenticated-orcid":false,"given":"G.","family":"Widhalm","sequence":"additional","affiliation":[]},{"given":"D.","family":"Surdez","sequence":"additional","affiliation":[]},{"given":"O.","family":"Delattre","sequence":"additional","affiliation":[]},{"given":"N.","family":"Andr\u00e9","sequence":"additional","affiliation":[]},{"given":"J.","family":"Stampfl","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5534-209X","authenticated-orcid":false,"given":"T.","family":"Toma\u0161i\u010d","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1439-5301","authenticated-orcid":false,"given":"S.","family":"Taschner-Mandl","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5942-0817","authenticated-orcid":false,"given":"M.","family":"Distel","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"386_CR1","unstructured":"WHO, \u201cCancer\u201d, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer (2022)."},{"key":"386_CR2","first-page":"3","volume":"17","author":"C Xu","year":"2019","unstructured":"Xu, C., Li, X., Liu, P., Li, M. & Luo, F. Patient-derived xenograft mouse models: a high fidelity tool for individualized medicine. Oncol Lett 17, 3\u201310 (2019).","journal-title":"Oncol Lett"},{"key":"386_CR3","doi-asserted-by":"publisher","unstructured":"Costa, B., Estrada, M. F., Mendes, R. V. & Fior, R. Zebrafish avatars towards personalized medicine\u2014a comparative review between avatar models. Cells 9, https:\/\/doi.org\/10.3390\/cells9020293 (2020).","DOI":"10.3390\/cells9020293"},{"key":"386_CR4","doi-asserted-by":"publisher","first-page":"E8234","DOI":"10.1073\/pnas.1618389114","volume":"114","author":"R Fior","year":"2017","unstructured":"Fior, R. et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proc. Natl Acad. Sci. USA 114, E8234\u2013E8243 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"386_CR5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/dvdy.20471","volume":"233","author":"LM Lee","year":"2005","unstructured":"Lee, L. M., Seftor, E. A., Bonde, G., Cornell, R. A. & Hendrix, M. J. The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev. Dyn. 233, 1560\u20131570 (2005).","journal-title":"Dev. Dyn."},{"key":"386_CR6","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1038\/nprot.2007.412","volume":"2","author":"S Nicoli","year":"2007","unstructured":"Nicoli, S. & Presta, M. The zebrafish\/tumor xenograft angiogenesis assay. Nat. Protoc. 2, 2918\u20132923 (2007).","journal-title":"Nat. Protoc."},{"key":"386_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1242\/dmm.015784","volume":"7","author":"CJ Veinotte","year":"2014","unstructured":"Veinotte, C. J., Dellaire, G. & Berman, J. N. Hooking the big one: the potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era. Dis. Model Mech. 7, 745\u2013754 (2014).","journal-title":"Dis. Model Mech."},{"key":"386_CR8","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.cell.2019.04.004","volume":"177","author":"C Yan","year":"2019","unstructured":"Yan, C. et al. Visualizing engrafted human cancer and therapy responses in immunodeficient zebrafish. Cell 177, 1903\u20131914.e1914 (2019).","journal-title":"Cell"},{"key":"386_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/1078-0432.CCR-14-2921","volume":"21","author":"J Barriuso","year":"2015","unstructured":"Barriuso, J., Nagaraju, R. & Hurlstone, A. Zebrafish: a new companion for translational research in oncology. Clin. Cancer Res. 21, 969\u2013975 (2015).","journal-title":"Clin. Cancer Res."},{"key":"386_CR10","doi-asserted-by":"publisher","unstructured":"Gauert, A. et al. Fast, in vivo model for drug-response prediction in patients with B-cell precursor acute lymphoblastic leukemia. Cancers 12, https:\/\/doi.org\/10.3390\/cancers12071883 (2020).","DOI":"10.3390\/cancers12071883"},{"key":"386_CR11","doi-asserted-by":"publisher","unstructured":"Cornet, C., Dyballa, S., Terriente, J. & Di Giacomo, V. ZeOncoTest: refining and automating the zebrafish xenograft model for drug discovery in cancer. Pharmaceuticals 13, https:\/\/doi.org\/10.3390\/ph13010001 (2019).","DOI":"10.3390\/ph13010001"},{"key":"386_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21421-y","volume":"12","author":"V Povoa","year":"2021","unstructured":"Povoa, V. et al. Innate immune evasion revealed in a colorectal zebrafish xenograft model. Nat. Commun. 12, 1156 (2021).","journal-title":"Nat. Commun."},{"key":"386_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13046-022-02280-x","volume":"41","author":"Z Ali","year":"2022","unstructured":"Ali, Z. et al. Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer. J. Exp. Clin. Cancer Res. 41, 58 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"386_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/d41573-019-00165-x","volume":"18","author":"M Cully","year":"2019","unstructured":"Cully, M. Zebrafish earn their drug discovery stripes. Nat. Rev. Drug Discov. 18, 811\u2013813 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"386_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cbpa.2014.10.025","volume":"24","author":"AJ Rennekamp","year":"2015","unstructured":"Rennekamp, A. J. & Peterson, R. T. 15 years of zebrafish chemical screening. Curr. Opin. Chem. Biol. 24, 58\u201370 (2015).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"386_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-0716-1020-6_19","volume":"2226","author":"S Pascoal","year":"2021","unstructured":"Pascoal, S. et al. Using zebrafish larvae as a xenotransplantation model to study Ewing sarcoma. Methods Mol. Biol. 2226, 243\u2013255 (2021).","journal-title":"Methods Mol. Biol."},{"key":"386_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/bs.mcb.2021.07.002","volume":"167","author":"S Grissenberger","year":"2022","unstructured":"Grissenberger, S. et al. Preclinical testing of CAR T cells in zebrafish xenografts. Methods Cell Biol. 167, 133\u2013147 (2022).","journal-title":"Methods Cell Biol."},{"key":"386_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.trecan.2020.03.012","volume":"6","author":"J Xiao","year":"2020","unstructured":"Xiao, J., Glasgow, E. & Agarwal, S. Zebrafish xenografts for drug discovery and personalized medicine. Trends Cancer 6, 569\u2013579 (2020).","journal-title":"Trends Cancer"},{"key":"386_CR19","doi-asserted-by":"publisher","first-page":"e85439","DOI":"10.1371\/journal.pone.0085439","volume":"9","author":"B Zhang","year":"2014","unstructured":"Zhang, B. et al. Quantitative phenotyping-based in vivo chemical screening in a zebrafish model of leukemia stem cell xenotransplantation. PLoS ONE 9, e85439 (2014).","journal-title":"PLoS ONE"},{"key":"386_CR20","doi-asserted-by":"publisher","first-page":"893655","DOI":"10.3389\/fphar.2022.893655","volume":"13","author":"M Hason","year":"2022","unstructured":"Hason, M. et al. Bioluminescent zebrafish transplantation model for drug discovery. Front. Pharmacol. 13, 893655 (2022).","journal-title":"Front. Pharmacol."},{"key":"386_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrd3480","volume":"10","author":"DC Swinney","year":"2011","unstructured":"Swinney, D. C. & Anthony, J. How were new medicines discovered. Nat. Rev. Drug Discov. 10, 507\u2013519 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"386_CR22","doi-asserted-by":"publisher","first-page":"e21768","DOI":"10.1371\/journal.pone.0021768","volume":"6","author":"C Zhao","year":"2011","unstructured":"Zhao, C. et al. A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors. PLoS ONE 6, e21768 (2011).","journal-title":"PLoS ONE"},{"key":"386_CR23","doi-asserted-by":"publisher","unstructured":"Haney, M. G., Moore, L. H. & Blackburn, J. S. Drug screening of primary patient derived tumor xenografts in zebrafish. J. Vis. Exp. https:\/\/doi.org\/10.3791\/60996 (2020).","DOI":"10.3791\/60996"},{"key":"386_CR24","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1038\/onc.2016.498","volume":"36","author":"GA Franzetti","year":"2017","unstructured":"Franzetti, G. A. et al. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation\/migration choices in Ewing sarcoma cells. Oncogene 36, 3505\u20133514 (2017).","journal-title":"Oncogene"},{"key":"386_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-14-36","volume":"14","author":"JN Wittbrodt","year":"2014","unstructured":"Wittbrodt, J. N., Liebel, U. & Gehrig, J. Generation of orientation tools for automated zebrafish screening assays using desktop 3D printing. BMC Biotechnol. 14, 36 (2014).","journal-title":"BMC Biotechnol."},{"key":"386_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-0716-1020-6_18","volume":"2226","author":"D Surdez","year":"2021","unstructured":"Surdez, D., Landuzzi, L., Scotlandi, K. & Manara, M. C. Ewing sarcoma PDX models. Methods Mol. Biol. 2226, 223\u2013242 (2021).","journal-title":"Methods Mol. Biol."},{"key":"386_CR27","doi-asserted-by":"publisher","unstructured":"Pascoal, S. et al. A Preclinical embryonic zebrafish xenograft model to investigate CAR T cells in vivo. Cancers 12, https:\/\/doi.org\/10.3390\/cancers12030567 (2020).","DOI":"10.3390\/cancers12030567"},{"key":"386_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1021\/bc00034a015","volume":"6","author":"PR Banks","year":"1995","unstructured":"Banks, P. R. & Paquette, D. M. Comparison of three common amine reactive fluorescent probes used for conjugation to biomolecules by capillary zone electrophoresis. Bioconjug. Chem. 6, 447\u2013458 (1995).","journal-title":"Bioconjug. Chem."},{"key":"386_CR29","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nm.1983","volume":"15","author":"HV Erkizan","year":"2009","unstructured":"Erkizan, H. V. et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing\u2019s sarcoma. Nat. Med. 15, 750\u2013756 (2009).","journal-title":"Nat. Med."},{"key":"386_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2017.05.027","volume":"403","author":"M Kollareddy","year":"2017","unstructured":"Kollareddy, M. et al. The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis. Cancer Lett. 403, 74\u201385 (2017).","journal-title":"Cancer Lett."},{"key":"386_CR31","doi-asserted-by":"publisher","unstructured":"Morice, S. et al. The YAP\/TEAD axis as a new therapeutic target in osteosarcoma: effect of verteporfin and CA3 on primary tumor growth. Cancers 12, https:\/\/doi.org\/10.3390\/cancers12123847 (2020).","DOI":"10.3390\/cancers12123847"},{"key":"386_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00294-8","volume":"10","author":"L Bierbaumer","year":"2021","unstructured":"Bierbaumer, L. et al. YAP\/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. Oncogenesis 10, 2 (2021).","journal-title":"Oncogenesis"},{"key":"386_CR33","first-page":"4399","volume":"10","author":"A Kaneda","year":"2020","unstructured":"Kaneda, A. et al. The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. Am. J. Cancer Res. 10, 4399\u20134415 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"386_CR34","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.21.00086","volume":"39","author":"A Bellini","year":"2021","unstructured":"Bellini, A. et al. Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1). J. Clin. Oncol. 39, 3377\u20133390 (2021).","journal-title":"J. Clin. Oncol."},{"key":"386_CR35","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","volume":"22","author":"M Fischer","year":"2021","unstructured":"Fischer, M. et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol. 22, 1764\u20131776 (2021).","journal-title":"Lancet Oncol."},{"key":"386_CR36","doi-asserted-by":"publisher","first-page":"216028","DOI":"10.1016\/j.canlet.2022.216028","volume":"554","author":"S Grissenberger","year":"2023","unstructured":"Grissenberger, S. et al. High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1\/BCL-X(L) inhibition against Ewing sarcoma. Cancer Lett. 554, 216028 (2023).","journal-title":"Cancer Lett."},{"key":"386_CR37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.molonc.2013.12.005","volume":"8","author":"SR Ambati","year":"2014","unstructured":"Ambati, S. R. et al. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Mol. Oncol. 8, 323\u2013336 (2014).","journal-title":"Mol. Oncol."},{"key":"386_CR38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejca.2021.08.022","volume":"157","author":"ADJ Pearson","year":"2021","unstructured":"Pearson, A. D. J. et al. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. Eur. J. Cancer 157, 198\u2013213 (2021).","journal-title":"Eur. J. Cancer"},{"key":"386_CR39","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Mosse","year":"2013","unstructured":"Mosse, Y. P. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study. Lancet Oncol. 14, 472\u2013480 (2013).","journal-title":"Lancet Oncol."},{"key":"386_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01583-z","volume":"21","author":"M Berlak","year":"2022","unstructured":"Berlak, M. et al. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. Mol. Cancer 21, 126 (2022).","journal-title":"Mol. Cancer"},{"key":"386_CR41","doi-asserted-by":"publisher","first-page":"108ra114","DOI":"10.1126\/scitranslmed.3002950","volume":"3","author":"SC Bresler","year":"2011","unstructured":"Bresler, S. C. et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci. Transl. Med. 3, 108ra114 (2011).","journal-title":"Sci. Transl. Med."},{"key":"386_CR42","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1038\/onc.2015.434","volume":"35","author":"DN Debruyne","year":"2016","unstructured":"Debruyne, D. N. et al. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT. Oncogene 35, 3681\u20133691 (2016).","journal-title":"Oncogene"},{"key":"386_CR43","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1089\/zeb.2016.1339","volume":"13","author":"L Hamilton","year":"2016","unstructured":"Hamilton, L., Astell, K. R., Velikova, G. & Sieger, D. A. Zebrafish live imaging model reveals differential responses of microglia toward glioblastoma cells in vivo. Zebrafish 13, 523\u2013534 (2016).","journal-title":"Zebrafish"},{"key":"386_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1089\/107632703762687582","volume":"9","author":"MC Kruyt","year":"2003","unstructured":"Kruyt, M. C. et al. Application and limitations of chloromethyl-benzamidodialkylcarbocyanine for tracing cells used in bone Tissue engineering. Tissue Eng. 9, 105\u2013115 (2003).","journal-title":"Tissue Eng."},{"key":"386_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/aja.1002030302","volume":"203","author":"CB Kimmel","year":"1995","unstructured":"Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of embryonic development of the zebrafish. Dev. Dyn. 203, 253\u2013310 (1995).","journal-title":"Dev. Dyn."},{"key":"386_CR46","unstructured":"Westerfield, M. The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio). 4th edition (2000)."},{"key":"386_CR47","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.celrep.2020.01.049","volume":"30","author":"MM Aynaud","year":"2020","unstructured":"Aynaud, M. M. et al. Transcriptional Programs Define Intratumoral Heterogeneity of Ewing Sarcoma at Single-Cell Resolution. Cell Rep. 30, 1767\u20131779.e1766 (2020).","journal-title":"Cell Rep."},{"key":"386_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature23647","volume":"549","author":"E Stewart","year":"2017","unstructured":"Stewart, E. et al. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549, 96\u2013100 (2017).","journal-title":"Nature"},{"key":"386_CR49","doi-asserted-by":"publisher","first-page":"e19305","DOI":"10.1371\/journal.pone.0019305","volume":"6","author":"C von Levetzow","year":"2011","unstructured":"von Levetzow, C. et al. Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS ONE 6, e19305 (2011).","journal-title":"PLoS ONE"},{"key":"386_CR50","doi-asserted-by":"publisher","unstructured":"Distel, M. & Koster, R. W. In vivo time-lapse imaging of zebrafish embryonic development. CSH Protoc. 2007, pdb prot4816, https:\/\/doi.org\/10.1101\/pdb.prot4816 (2007).","DOI":"10.1101\/pdb.prot4816"},{"key":"386_CR51","doi-asserted-by":"publisher","first-page":"e43850","DOI":"10.1371\/journal.pone.0043850","volume":"7","author":"J Maes","year":"2012","unstructured":"Maes, J. et al. Evaluation of 14 organic solvents and carriers for screening applications in zebrafish embryos and larvae. PLoS ONE 7, e43850 (2012).","journal-title":"PLoS ONE"},{"key":"386_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1124\/jpet.119.260299","volume":"371","author":"RC Van Wijk","year":"2019","unstructured":"Van Wijk, R. C. et al. Mechanistic and quantitative understanding of pharmacokinetics in zebrafish larvae through nanoscale blood sampling and metabolite modeling of paracetamol. J. Pharmacol. Exp. Ther. 371, 15\u201324 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"386_CR53","doi-asserted-by":"publisher","first-page":"106311","DOI":"10.1016\/j.bioorg.2022.106311","volume":"131","author":"Z Zajec","year":"2023","unstructured":"Zajec, Z., Dernovsek, J., Distel, M., Gobec, M. & Tomasic, T. Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel Hsp90 C-terminal domain inhibitors against Ewing sarcoma. Bioorg. Chem. 131, 106311 (2023).","journal-title":"Bioorg. Chem."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-023-00386-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-023-00386-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-023-00386-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:03:09Z","timestamp":1684393389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-023-00386-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["386"],"URL":"https:\/\/doi.org\/10.1038\/s41698-023-00386-9","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"7 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}